An Update on Psychopharmacologic Medication: What Teachers, Clinicians, and Parents Need to Know

Intervention in School and Clinic

Volumn 33, Issue 1, 1997, Pages 4-21

  Sweeney, Dwight P ^a   Forness, Steven R ^b   Kavale, Kenneth A ^b   Levitt, Jennifer G ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0010212349     PISSN: 10534512     EISSN: None     Source Type: Journal    
DOI: 10.1177/105345129703300103     Document Type: Article

References (55)

1. Alderton, H. R. (1995). Tricyclic medication in children and the QT interval: Case report and discussion. Canadian Journal of Psychiatry, 40, 325-329.
2. Alessi, N., Naylor, M. W., Ghaziuddin, M., & Zubieta, J. K. (1994). Update on lithium carbonate therapy in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 33(3), 291-304.
3. Allen, A. J., Leonard, H., & Swedo, S. E. (1995). Current knowledge of medications for the treatment of childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 34(8), 976-986.
4. Aman, M. G., & Wolford, P. L. (1995). Consumer satisfaction with involvement in drug research: A social validity study. Journal of the American Academy of Child and Adolescent Psychiatry, 34(7), 940-945.
5. American Psychiatric Association. (1994). Statistical manual of mental disorders, (4th ed.). Washington, DC: Authors.
6. Baldessarini, R. J., & Teicher, M. H. (1995). Dosing of antipsychotic agents in pediatric populations. Journal of Child and Adolescent Psychopharmacology, 5(1), 1-4.
7. Barkley, R. A. (1977). A review of stimulant drug research with hyperactive children. Child Psychology and Psychiatry, 27, 137-165.
8. Barkley, R. A. (1990). Hyperactive children: A handbook for diagnosis and treatment. New York: Guilford Press.
9. Barrickman, L. L., Perry, P. J., Allen, A. J., Kuperman, S., Arndt, S. V., Herrmann, K. J., & Schumacher, E. (1995). Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 34(5), 649-657.
10. Bastianens, L., & Bastianens, D. K. (1993). A manual of psychiatric medications for teenagers. Journal of Child and Adolescent Psychopharmacology, 3, 175, M1-M59.
11. Biederman, J. (1996). Introduction: Contemporary perspectives on pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 34(10), 1274-1275.
12. Bird, H. R., Gould, M. S., & Staghezza, B. M. (1993). Patterns of comorbidity in a community sample of children aged 9 through 16 years. Journal of the American Academy of Child and Adolescent Psychiatry, 32(3), 361-368.
13. Birmaher, B. (1996). Clozapine for child and adolescent schizophrenia. Child & Adolescent Psychopharmacology News, 1(3), 1-4.
14. Campbell, M., Adams, P. B., Small, A. M., Kafantaris, V., Silva, R. R., Shell, J., Perry, R., & Overall, J. E. (1995). Lithium in hospitalized aggressive children with conduct disorder: A double-blind and placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry, 34(54), 445-453.
15. Campbell, M., & Cueva, J. E. (1995). Psychopharmacology in child and adolescent psychiatry: A review of the past seven years. Part II. Journal of the American Academy of Child and Adolescent Psychiatry, 34(10), 1262-1271.
16. Cantwell, D. P. (1996). Attention deficit disorder: A review of the past 10 years. Journal of the American Academy of Child and Adolescent Psychiatry, 34(10), 978-987.
17. Carlson, G. A., Rapport, M. D., Kelly, K. L., & Pataki, C. S. (1995). Methylphenidate and desipramine in hospitalized children with comorbid behavior and mood disorders: Separate and combined effects on behavior and mood. Journal of Child and Adolescent Psychopharmacology, 5(3), 191-204.
18. Costello, A. J., Dulcun, M. K., & Kalas, R. (1991). A checklist of hospitalization criteria for use with children. Hospital Community Psychiatry, 42(8), 823.
19. Fava, M. (1996). Traditional and alternative research designs and methods in clinical pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 34(10), 1292-1303.
20. Fleck, S. (1995). Dehumanizing developments in American psychiatry in recent decades. Journal of Nervous and Mental Disease, 183, 195-203.
21. Forness, S. R., & Kavale, K. A. (1988). Psychopharmacologic treatment: A note on classroom effects. Journal of Learning Disabilities, 21(3), 144-147.
22. Forness, S. R., Swanson, J. M., Cantwell, D. P., Guthrie, D., & Sena, R. (1992). Response to stimulant medication across six measures of school-related performance in children with ADHD and disruptive behavior. Behavioral Disorders, 18, 42-53.
23. Forness, S. R., Sweeney, D. P., & Toy, K. (1996). Psychopharmacologic medication: What teachers need to know. Beyond Behavior, 7(2), 4-11.
24. Frazier, J. A., Gordon, C. T., McKenna, K., Lenane, M. C., Jih, D., & Rapoport, J. L. (1994). An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 33(5), 658-663.
25. Gadow, K. D. (1992). Pediatric psychopharmacology: A review of recent research. Journal of Child Psychology and Psychiatry, 33, 153-195.
26. Glantz, L. H. (1996). Conducting research with children: legal and ethical issues. Journal of the American Academy of Child and Adolescent Psychiatry, 34(10), 1283-1291.
27. Greenhill, L. L., Abikoff, H. B., Arnold, E., Cantwell, D. P., Conners, C. K., Elliott, G., Hechtman, L., Hinshaw, S. P., Hoza, B., Jensen, P. S., March, J. S., Newcorn, J., Pelham, W. E., Severe, J. B., Swanson, J. M., Vitiello, B., & Wells, K. (1996). Medication treatment strategics in the MTA study: Relevance to clinicians and researchers. Journal of the American Academy of Child and Adolescent Psychiatry, 34(10), 1304-1313.
28. Hallfors, D., Watson, K., & Fallon, T. (1995). An examination of psychotropic drug treatment for children with serious emotional disturbances. Waltham, MA: Brandeis University, Heller School, Family and Children's Policy Center.
29. Hunt, R. D., Capper, L., & O'Connell, P. (1990). Clonidine in child and adolescent psychiatry. Journal of Child and Adolescent Psychopharmacology, 1(1), 87-101.
30. Jensen, P. S. (1993). Development and implementation of multimodal and combined treatment studies in children and adolescents: NIMH perspectives. Psychopharmacohgy Bulletin, 29, 19-26.
31. Kaplan, S. L., Simms, R. M., & Busner, J. (1994). Prescribing practices of outpatient child psychiatrists. Journal of the American Academy of Child and Adolescent Psychiatry, 33(1), 35-44.
32. Keltner, N. L., & Folks, D. G. (1993). Psychotropic drugs. St. Louis: Mosby.
33. Konopasek, D. E. (1996). Medication "Fact Sheets": A medication reference guide for the non-medical professional. Anchorage: Arctic Tern. (Available from Dean E. Konopasek, PO Box 111994, Anchorage, AK 99511-1994)
34. Kopala, L. C. (1996). Risperidone for child and adolescent schizophrenia. Child & Adolescent Psychopharmacology News, 1(2), 1-4.
35. Kowatch, R. A., Suppes, T., Gilfillan, S. K., Fuentes, R. M., Grannemann, B. D., & Emslie, G. J. (1995). Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: A clinical case series. Journal of Child and Adolescent Psychopharmacology, 5(4), 241-253.
36. Laughren, T. P. (1996). Regulatory issues in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 34(10), 1276-1282.
37. Leonard, H. L., Meyer, M. C., Swedo, S. E., Richter, D., Hamburger, S. D., Allen, A. J., Rapoport, J. L., & Tucker, E. (1995). Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1460-1468.
38. Mandoki, M. W. (1995). Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side effects? Journal of Child and Adolescent Psychopharmacology, 5(1), 49-67.
39. McClellan, J., & Werry, J. (1994). Practice parameters for assessment and treatment of children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 33(5), 616-635.
40. McConville, B. J., Minnery, K. L., Sorter, M. T., West, S. A., Friedman, L. M., & Christian, K. (1996). An open study of the effects of sertraline on adolescent major depression. Journal of Child and Adolescent Psychopharmacology, 6(1), 41-51.
41. Pelham, W. E., Swanson, J. M., Furman, M. B., & Schwindt, H. (1995). Pemoline effects on children with ADHD: A time-response by dose-response analysis on classroom measures. Journal of the American Academy of Child and Adolescent Psychiatry, 34(11), 1504-1513.
42. Popper, C. W. (1987). Medical unknowns and ethical consent: Prescribing psychotropic medications for children in the face of uncertainty. In C. W. Popper (Ed.), Psychiatric pharmacosciences of children and adolescents (pp. 212-221). Washington, DC: American Psychiatric Press.
43. Popper, C. W. (1995). Combining methylphenidate and clonidine: Pharmacologic questions and news reports about sudden death. Journal of Child and Adolescent Psychopharmacology, 5, 157-166.
44. Popper, C. W., & Zimnitzky, B. (1996). Child and adolescent psychopharmacology update: January 1995-December 1995. Journal of Child and Adolescent Psychopharmacology, 6(2), 85-118.
45. Quintana, H., & Keshavan, M. (1995). Case study: Risperidone in children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 34(10), 1292-1296.
46. Remschmidt, H., Schulz, E., & Martin, M. (1994). An open trial of clozapine in 36 adolescents with schizophrenia. Journal of Child and Adolescent Psychopharmacology, 4(1), 31-41.
47. The Robert Wood Johnson Foundation, Harvard School of Public Health, & Louis Harris and Associates. (1995, August 30). Sick people in managed care have difficulty getting services and treatment. Medical Benefits, 12(16), 6-7.
48. Rosenberg, D. R., Holttum, J., & Gershon, S. (1994). Textbook of pharmacotherapy for child and adolescent psychiatric disorders. New York: Brunner/Mazel.
49. Safer, D. (1995). Medication usage trends for ADD. Attention, 2(2), 11-15.
50. Simeon, J. G., Carrey, N. J., Wiggins, D. M., Milin, R. P., & Hosenbocus, S. N. (1995). Risperidone effects in treatment resistant adolescents: Preliminary case reports. Journal of Child and Adolescent Psychopharmacology, 5(1), 69-79.
51. Stine, J. J. (1994). Psychosocial and psychodynamic issues affecting noncompliance with psychostimulant treatment. Journal of Child and Adolescent Psychopharmacology, 4(1), 75-86.
52. Swanson, J. M., Flockhart, D., Udrea, D., Cantwell, D., Connor, D., & Williams, L. (1995). Clonidine in the treatment of ADHD: Questions about safety and efficacy [letter]. Journal of Child and Adolescent Psychopharmacology, 5, 301-304.
53. Tierney, E., Joshi, P., Llinas, J. F., Rosenberg, L. A., & Riddle, M. A. (1995). Sertraline for major depression in children and adolescents: Preliminary clinical experience. Journal of Child and Adolescent Psychopharmacology, 5(1), 13-27.
54. Werkman, S. (1993). The role of medication in treatment of childhood depression. Journal of Emotional and Behavioral Problems, 2(2), 42-44.
55. Wilens, T. E., Spencer, T., Biederman, J., Wozniak, J., & Connor, D. (1995). Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 34(1), 110-112.